Trinity Biotech plc (TRIB) reported its fourth‑quarter 2025 financial results on May 1 2026, showing a like‑for‑like revenue of $11.0 million, a net loss of $17.5 million, and an adjusted EBITDA of negative $0.5 million. The company’s gross margin rose to 35.2 % from 30.8 % in the same quarter a year earlier, reflecting a modest improvement in cost efficiency despite a decline in top‑line sales.
Cash on hand at the end of the quarter was $1.3 million, down sharply from $5.2 million at the end of 2024. The company did not report operating cash outflows for the quarter, and no reliable figure was available in the fact‑check sources.
The revenue decline was driven primarily by lower HIV test sales, which were affected by timing variability in orders and a transition to new manufacturing and supply‑chain processes. The company’s Comprehensive Transformation Plan, which includes consolidating and offshoring production, is expected to reduce costs and improve margins over time.
Management highlighted progress on the transformation plan, noting that cost‑control initiatives are beginning to yield margin gains and that the company is on track to achieve adjusted EBITDA positivity and cash‑flow positivity from operations starting in Q3 2025. The focus remains on optimizing manufacturing and supply‑chain operations to support future growth.
The results underscore a challenging revenue environment, with the HIV testing market experiencing disruptions due to changes in international aid funding and manufacturing transition effects. However, the narrowing of the adjusted EBITDA loss and the improvement in gross margin suggest that the company’s cost‑control measures are taking effect. The significant drop in cash reserves, partly attributable to a $10 million IFRS charge related to financing restructuring, highlights liquidity constraints that the company must manage as it continues its transformation.
Additional context includes the company’s ongoing product development, such as the continuous glucose monitoring device and the IFCC Gold‑classified Premier HbA1c 9210™ platform, as well as a recent leadership appointment of Jerry Lydon as Head of North America Commercial Operations to strengthen revenue quality and profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.